United States v. 50 Acres of Land

Sigyn Therapeutics™ Announces Completion of Animal Studies

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Observation, United States v. 50 Acres of Land, Achievement, Death, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Securities Exchange Act of 1934, University, Inflammation, Security (finance), Septic shock, Annual report, IACUC, CRRT, Therapy, Cytokine, Innovation, Company, Ammonia, Hemofiltration, Hepatic encephalopathy, CA, IL-6, U.S. Securities and Exchange Commission, Community-acquired pneumonia, Food, Adult, Blood, Institutional Animal Care and Use Committee, Severe acute respiratory syndrome coronavirus 2, Sepsis, Infection, Global health, FDA, IDE, SAN, Securities Act of 1933, TNF, IBT, Technology, Drug Quality and Security Act, Bioterrorism, Seminal vesicles, CEO, OTC Markets Group, Hospital, Peptidoglycan, Pharmaceutical industry, Medical device, Vaccine

SAN DIEGO, CA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis, today reported the successful completion of an in vivo animal study that demonstrated Sigyn Therapy to be safe and well tolerated.

Key Points: 
  • Overall, Sigyn Therapy was well tolerated by all eight animal subjects and no serious adverse events were reported in any treated animal.
  • Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide.
  • Beyond these broad-spectrum capabilities, animal studies have demonstrated the safe administration of Sigyn Therapy.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Sigyn Therapeutics to Present at the Bullseye Small Cap Virtual Investor Conference

Retrieved on: 
Tuesday, January 25, 2022
U.S. Securities and Exchange Commission, Hemofiltration, Risk, Septic shock, Sepsis, Hepatic encephalopathy, COVID-19, IL-6, United States v. 50 Acres of Land, Securities Exchange Act of 1934, Securities Act of 1933, TNF, Blood, Bioterrorism, Ammonia, Inflammation, Therapy, Security (finance), Company, Annual report, Hospital, CRRT, Infection, Death, Community-acquired pneumonia, Pharmaceutical industry

To support widespread implementation, Sigyn Therapy is a single-use disposable device designed for use on the established infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines located in hospitals and clinics worldwide.

Key Points: 
  • To support widespread implementation, Sigyn Therapy is a single-use disposable device designed for use on the established infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines located in hospitals and clinics worldwide.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.
  • Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements.
  • These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect.

Sigyn Therapeutics Announces Presentation at Today’s Emerging Growth Conference

Retrieved on: 
Wednesday, January 5, 2022
Investment, Septic shock, Therapy, COVID-19, Community-acquired pneumonia, Securities Act of 1933, Bioterrorism, United States v. 50 Acres of Land, Company, Blood, CRRT, IL-6, Infection, Securities Exchange Act of 1934, Sepsis, Growth, Conference, U.S. Securities and Exchange Commission, Hemofiltration, Annual report, Security (finance), Risk, CEO, Ammonia, Hospital, Inflammation, OTC Markets Group, Hepatic encephalopathy, SAN, GLOBE, TNF, Death, Pharmaceutical industry

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: SIGY),a medical technology company focused on the treatment of pathogen-related conditions that precipitate sepsis,announced that its Chairman and CEO, Jim Joyce, will give a corporate presentation at todays virtual Emerging Growth Conference.

Key Points: 
  • SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: SIGY),a medical technology company focused on the treatment of pathogen-related conditions that precipitate sepsis,announced that its Chairman and CEO, Jim Joyce, will give a corporate presentation at todays virtual Emerging Growth Conference.
  • The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth.
  • Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Sigyn Therapeutics CEO Note: 2021 Milestone Achievements / 2022 Clinical Progression / Images of Sigyn Therapy in Action

Retrieved on: 
Tuesday, January 4, 2022
Safety, Securities Exchange Act of 1934, COVID-19, CRRT, Hepatic encephalopathy, U.S. Securities and Exchange Commission, Blood, Community-acquired pneumonia, FDA, IL-6, SAN, GLOBE, Toxin (comics), Sepsis, Bioterrorism, Company, OTC Markets Group, CEO, Hospital, Inflammation, Annual report, Septic shock, United States v. 50 Acres of Land, Therapy, TNF, Drug Quality and Security Act, IDE, Death, Efficiency, Ammonia, Security (finance), Global health, Infection, Hemofiltration, Face, Risk, Industry, Securities Act of 1933, Medical device, Pharmaceutical industry, Vaccine

In the face of a pandemic that paused and shuttered numerous clinical research programs, we translated our vision for Sigyn Therapy from conceptual design to clinical application in 2021.

Key Points: 
  • In the face of a pandemic that paused and shuttered numerous clinical research programs, we translated our vision for Sigyn Therapy from conceptual design to clinical application in 2021.
  • Milestone achievements in the past year establish Sigyn Therapy as an emergent strategy to address a wide-range of pathogen-related conditions that precipitate sepsis, the #1 cause of hospital deaths worldwide.
  • Concurrent with these achievements, we established manufacturing procedures to support a final design of Sigyn Therapy that improved bloodstream turnover efficiency and expanded our capacity to extract therapeutic targets.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis

Retrieved on: 
Wednesday, December 1, 2021
CRRT, IDE, Hepatic encephalopathy, CEO, Blood, Septic shock, MRSA, Industry, Sepsis, Death, Company, Hospital, OTC Markets Group, Private Securities Litigation Reform Act, Virus, IL-6, Inflammation, Ammonia, COVID-19, Bioterrorism, Cytokine, United States v. 50 Acres of Land, Peptidoglycan, LTA, Community-acquired pneumonia, Risk, GLOBE, Adult, FDA, In vitro, PG, Infection, CA, Therapy, Failure, TNF, Hemofiltration, Vaccine, Pharmaceutical industry

SAN DIEGO, CA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of pathogen-associated indications that precipitate sepsis, today announced that preclinical invitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma.

Key Points: 
  • The invitro clearance of both targets was rapid, with an ~50% reduction of PG at one hour and a ~70% reduction of LTA at two hours.
  • In addition to being potent activators of sepsis, there is a heightened interest in gram-positive pathogens based on the continuing emergence of drug resistant species, including antibiotic-resistant Staphylococcus aureus (MRSA).
  • Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated indications that precipitate sepsis, the #1 cause of hospital deaths worldwide.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.